Bioequivalence Study Comparing the Pharmacokinetics and Glucodynamics of LY2963016 U-200 Formulation With LY2963016 U-100 Formulation in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 23 Mar 2017
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 20 Mar 2017 Status changed from recruiting to completed.
- 20 Jan 2017 Planned End Date changed from 1 Jul 2017 to 8 Sep 2017.
- 20 Jan 2017 Planned primary completion date changed from 1 Jul 2017 to 8 Sep 2017.